To determine the clinical profile and efficacy of accelerated recombinant tissue-type
plasminogen activator (rt-PA) dose regimens, five different strategies of thrombolytic therapy …

Objectives. Our aim was to design and evaluate a new and easily administered recombinant
tissue-type plasminogen activator (rt-PA) regimen for thrombolysis in acute myocardial …

An intravenous infusion of 40 mg of recombinant tissue-type plasminogen activator (rt-PA)
was given intravenously over 90 minutes to 123 patients with acute myocardial infarction …

To improve further the patency rate of infarct-related coronary arteries, the following
accelerated dosage regimen of recombinant tissue-type plasminogen activator (rt-PA) was …

Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) and anisoylated
plasminogen streptokinase activator (APSAC) in myocardial infarction has been proved to …

Objectives. The present study was designed to test the efficacy and safety of a sequential
combination of recombinant tissue-type plasminogen activator (rt-PA) and pro-urokinase in …

Clot dissolution with restoration of infarct-related artery blood flow is the likely mechanism for
the improved prognosis and mortality reduction seen after thrombolytic therapy of acute …

Because a previous study utilizing a combination of recombinant tissue-type plasminogen
activator (rt-PA) and urokinase demonstrated reduced reocclusion rates compared with rates …

Fundamental observations and the conceptual framework underlying coronary thrombolysis
have a history dating back to 1789. Recent enthusiasm for it is predicated on the recently …

To assess the utility of percutaneous transluminal coronary angioplasty after successful
thrombolytic therapy for patients with acute myocardial infarction, the outcome of 201 …